Schaller G, Bangemann N, Becker C, Bühler H, Opri F, Weitzel H K
Department of Gynecology and Obstetrics, University Hospital Benjamin Franklin, Free University of Berlin, Germany.
J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):520-4. doi: 10.1007/s004320050311.
The HER2 protein, a member of the epidermal growth factor family, is encoded by the protooncogene c-erbB-2. Its overexpression, occurring in approximately one-third of all breast carcinomas, is associated with a poor prognosis. A humanized mouse antibody against HER2 has been developed by genetic engineering. Here an unspecific human IgG was connected to the recognizing mouse IgG fragment. The allergization typical for allogeneic antibodies does not take place in this context. The effectiveness of this antibody has been confirmed by two international prospective phase III trials that tested it alone and combined with chemotherapy. Both modes of application increased the response rates and the time to progression. Side-effects were rare except for a high rate of cardiac dysfunction when the antibody was combined with anthracyclines. The effectiveness and negligible side-effects of the chimeric antibody against HER2 (Herceptin) render it a valuable tool in the treatment of breast cancer.
HER2蛋白是表皮生长因子家族的成员之一，由原癌基因c-erbB-2编码。它在大约三分之一的乳腺癌中过度表达，与预后不良相关。一种针对HER2的人源化小鼠抗体已通过基因工程研发出来。在此，一种非特异性人IgG与识别性小鼠IgG片段相连。在这种情况下不会发生同种异体抗体典型的过敏反应。该抗体的有效性已通过两项国际前瞻性III期试验得到证实，这两项试验分别单独测试了该抗体以及将其与化疗联合使用。两种应用方式均提高了缓解率和疾病进展时间。除了抗体与蒽环类药物联合使用时心脏功能障碍发生率较高外，副作用很少见。针对HER2的嵌合抗体（赫赛汀）的有效性和可忽略不计的副作用使其成为治疗乳腺癌的一种有价值的工具。
